© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Thyroid Cancers
A 73-Year-Old Woman With Differentiated Thyroid Cancer
September 25, 2020
Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.
Early Data Presented for Lenvatinib and Pembrolizumab in Thyroid Cancer
September 23, 2020
Christine Dierks, MD, discusses the early data from a study looking at the combination of lenvatinib and pembrolizumab in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.
Larotrectinib Induces Promising Response Rate in Patients With Differentiated Thyroid Cancer
September 21, 2020
Larotrectinib as treatment of patients with TRK fusion-positive thyroid cancer had rapid and durable disease control, with the highest response rates observed in the differentiated thyroid cancer population.
A 71-Year-Old Woman with NTRK Gene Fusion Thyroid Cancer
September 21, 2020
A key opinion leader reviews the case of a 71-year-old woman with NTRK gene fusion thyroid cancer and considers novel therapies available for the management of her disease.
Larotrectinib Elicits Rapid, Durable Responses in TRK Fusion-Positive Solid Tumors
September 20, 2020
Larotrectinib demonstrated rapid and durable as treatment of patients with TRK fusion-positive solid tumors, as well as a favorable long-term toxicity profile, according to an expanded pooled analysis from 3 clinical trials.
Ongoing ARROW Trial Data Support Pralsetinib as a Potential Treatment Option in RET-Mutant MTC
September 20, 2020
Patients with medullary thyroid cancer harboring abberations in RET who were treated with pralsetinib across therapy lines exhibited potent and durable clinical activity, according to results presented at the ESMO Virtual Congress 2020 from the phase 1/2 ARROW clinical trial.
Pembrolizumab/Lenvatinib Combo Achieves Promising Responses in Anaplastic Thyroid Cancer
September 19, 2020
Christine Dierks, MD, discusses the results from the prospective phase 2 ATLEP study of lenvatinib in combination with pembrolizumab as treatment of patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.
FDA Grants Orphan Drug to Bispecific Antibody as Treatment of Thymic Epithelial Tumors
September 08, 2020
The FDA granted an Orphan Drug designation to KNO46 for the treatment of thymic epithelial tumors.
FDA Grants Priority Review to Pralsetinib for RET+ Thyroid Cancers
September 05, 2020
The FDA has granted a priority review to pralsetinib for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer as well as for patients with RET fusion–positive thyroid cancer.
Fusion Genes Associated With More Aggressive Papillary Thyroid Cancer in Pediatric Patients
September 03, 2020
The most common genetic cause of alterations in pediatric patients with papillary thyroid cancer were fusion genes, which were associated with more aggressive disease.